The hybrid molecule, VCP746, is a potent adenosine A2B receptor agonist that stimulates anti-fibrotic signalling

Biochem Pharmacol. 2016 Oct 1:117:46-56. doi: 10.1016/j.bcp.2016.08.007. Epub 2016 Aug 9.

Abstract

We have recently described the rationally-designed adenosine receptor agonist, 4-(5-amino-4-benzoyl-3-(3-(trifluoromethyl)phenyl)thiophen-2-yl)-N-(6-(9-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxylmethyl)tetrahydro-furan-2-yl)-9H-purin-6-ylamino)hexyl)benzamide (VCP746), a hybrid molecule consisting of an adenosine moiety linked to an adenosine A1 receptor (A1AR) allosteric modulator moiety. At the A1AR, VCP746 mediated cardioprotection in the absence of haemodynamic side effects such as bradycardia. The current study has now identified VCP746 as an important pharmacological tool for the adenosine A2B receptor (A2BAR). The binding and function of VCP746 at the A2BAR was rigorously characterised in a heterologous expression system, in addition to examination of its anti-fibrotic signalling in cardiac- and renal-derived cells. In FlpInCHO cells stably expressing the human A2BAR, VCP746 was a high affinity, high potency A2BAR agonist that stimulated Gs- and Gq-mediated signal transduction, with an apparent lack of system bias relative to prototypical A2BAR agonists. The distinct agonist profile may result from an atypical binding mode of VCP746 at the A2BAR, which was consistent with a bivalent mechanism of receptor interaction. In isolated neonatal rat cardiac fibroblasts (NCF), VCP746 stimulated potent inhibition of both TGF-β1- and angiotensin II-mediated collagen synthesis. Similar attenuation of TGF-β1-mediated collagen synthesis was observed in renal mesangial cells (RMC). The anti-fibrotic signalling mediated by VCP746 in NCF and RMC was selectively reversed in the presence of an A2BAR antagonist. Thus, we believe, VCP746 represents an important tool to further investigate the role of the A2BAR in cardiac (patho)physiology.

Keywords: Adenosine; Adenosine A(2B) receptor; Angiotensin II (PubChem CID: 172198); BAY60-6583 (PubChem CID: 11717831); Bivalent agonist; Collagen; DPCPX (PubChem CID: 1329); Fibroblasts; NECA (PubChem CID: 448222); PSB-603 (PubChem CID: 44185871); SCH442416 (PubChem CID: 10668061); SLV320 (PubChem CID: 9953065); TGF-β1 (PubChem CID: 56842206); [3H]DPCPX (PubChem CID: 53319341).

Publication types

  • Comparative Study

MeSH terms

  • Adenosine / analogs & derivatives*
  • Adenosine / pharmacology
  • Adenosine A2 Receptor Agonists / metabolism
  • Adenosine A2 Receptor Agonists / pharmacology*
  • Allosteric Regulation / drug effects
  • Animals
  • Animals, Newborn
  • Binding, Competitive
  • CHO Cells
  • Cell Line
  • Cells, Cultured
  • Collagen / antagonists & inhibitors*
  • Collagen / biosynthesis
  • Cricetulus
  • Fibrosis
  • Humans
  • Ligands
  • Mesangial Cells / cytology
  • Mesangial Cells / drug effects*
  • Mesangial Cells / metabolism
  • Mesangial Cells / pathology
  • Myoblasts, Cardiac / cytology
  • Myoblasts, Cardiac / drug effects*
  • Myoblasts, Cardiac / metabolism
  • Myoblasts, Cardiac / pathology
  • Protective Agents / pharmacology*
  • Radioligand Assay
  • Rats
  • Rats, Sprague-Dawley
  • Receptor, Adenosine A2B / chemistry
  • Receptor, Adenosine A2B / genetics
  • Receptor, Adenosine A2B / metabolism*
  • Recombinant Proteins / chemistry
  • Recombinant Proteins / metabolism
  • Signal Transduction / drug effects*
  • Thiophenes / pharmacology*

Substances

  • Adenosine A2 Receptor Agonists
  • Ligands
  • Protective Agents
  • Receptor, Adenosine A2B
  • Recombinant Proteins
  • Thiophenes
  • VCP746
  • Collagen
  • Adenosine